Nov 20, 2014
CBD, Edward Maier, Iowa, Iowa General Assembly, Iowa Pharmacy Board, Medical Cannabinoid Act, Monona, Schedule I, Schedule II
After some members expressed reservations, the Iowa Pharmacy Board decided on Wednesday to delay its decision on marijuana’s drug classification until January.
A board subcommittee initially recommended that the entire board consider reclassifying the substance from a Schedule I drug to a Schedule II drug. The recommendation was based on marijuana’s use for medical purposes, bolstered by a new law in Iowa that made the use of CBD oil, which is derived from the marijuana plant, legal for the treatment of children with epilepsy.
An Iowa Pharmacy Board member and pharmacist from Monona, Edward Maier, read the subcommittee’s recommendation:
“While the board believes that marijuana has a high potential for abuse, in 2014 the Iowa General Assembly passed the Medical Cannabinoid Act. The act permits the use of cannanbidiol for patients suffering from intractable epilepsy. The passage of this act is an affirmative recognition by the Iowa General Assembly that there is a medical use for marijuana. Continued placement for marijuana in Schedule I is not consistent with that act,” Maier said, reading directly from the recommendation.
Maier also emphasized that even if the Iowa Pharmacy Board decided to reclassify marijuana as a Schedule II substance, the decision would not necessarily mean the de facto implementation of a medical marijuana law in Iowa. The move would also necessitate legislative and regulatory action.
In the end, however, the entire board voted unanimously to delay the decision until they are scheduled to meet again the first week of January.